Thia Ventures

Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth. Taiwania Capital is a venture capital that focuses on investing in technologies and biotech areas start-ups that are Taiwan or US-based with disruptive and advanced technology. Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Positron Ventures helps and funds Europe-based scientist-entrepreneurs who are pursuing moonshots for (planetary) health. We invest in scientist-entrepreneurs working on a breakthrough in their field, across the natural sciences. We back teams from day one in their pursuit of solving a major global challenge. We do this with pre-seed investments and, wherever needed, support across all aspects of building a company. If you are looking for funding, check out our investment criteria and shopping list, and our view on when to engage. If you think there might be a match, contact us at startups@positron.vc. Scientists who have not yet spun out a company but are interested in doing so, please check our scientist resources.

Bioqube Ventures is a specialist life sciences investment firm based in Europe and US with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Bioqube Ventures is dedicated to funding therapeutic innovations: … a life sciences venture capital fund – dedicated to advancing exciting science in European and US ecosystems to breakthrough therapies for patients. … a fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for venture creation projects that require additional experiments prior to creating new ventures. With our in-house factory model we are able to translate exciting science into trailblazing companies. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.

Aegis Ventures is an next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on three key areas: data and automation, health and wellness, and emerging sciences and technologies. "In business‌‌,‌‌ I am driven by two things - building value through knowledge and improving the world through investment‌‌.‌‌ ‌‌A‌egis V‌entures is where I translate these passions into reality‌.‌" - Aegis Chairman, Bill Schoenfeld ‌A‌egis draws on decades of experience executing $20B of global transactions since Bill Schoenfeld's founding of‌‌ A‌‌PL Group in 1994‌‌.‌‌ Differentiated Skillset & Philosophy While building businesses is equal parts art and science‌‌,‌‌ we have found that many elements of the venture creation process are identif‌iable and replicable - and can be learned by a broad array of talented individuals‌‌.‌‌ Our venture creation playbook is founded on the expertise we have formed in other asset classes and is built on the understanding that success depends upon our ability to cultivate exceptional talent across the studio‌‌.‌‌ Financial Strength & Flexibility ‌A‌ll of our capital is internal‌‌,‌‌ and we are free to invest in the time and manner we see f‌it‌‌.‌‌ With no predetermined time horizon for realizing returns‌‌,‌‌ we are empowered to pursue long‑term‌‌,‌‌ structural theses in high‑magnitude opportunities‌‌.‌‌ Freed from the burdens of fundraising‌‌,‌‌ the full breadth of our focus is devoted to the advancement of our portfolio companies and the improvement of our platform‌‌.‌‌ Incisive Risk Management ‌A‌‌egis's unif‌ied risk framework aims to identify‌‌,‌‌ track‌‌,‌‌ and execute upon distinct risk reduction milestones that maximize upside potential and minimize downside exposure‌‌.‌‌ This analytical rigor allows our entrepreneurs to develop a disciplined‌‌,‌‌ methodical approach to venture creation‌ to vet and validate ideas with greater eff‌iciency and effectiveness‌‌.‌‌

Empowering life science innovators to reach their full potential by providing strategic financial guidance and unlocking global investment opportunities. Your Strategic Partner for Fundraising in Life Sciences Our proven track record makes us your trusted partner for your fundraising journey 2 exits in 2024 through Gold Nest Capital - Group's asset management company USD 50 M raised in 2024 for life science companies 151 company due diligences since 2020 as investment opportunities/services 100% client satisfaction for three years running 75% requests to renew for three years running 1 biomanufacturing company founded in 2023

We invest in early-stage opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takeda’s R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. Our aim is to access and support therapeutic and platform innovation working closely with academic innovators, entrepreneurs and investors. We invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.